Sign In
Buy XERS
$5.89
-0.110 (-1.83%)
At Close: Jun 03, 2026
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
05:55pm, Thursday, 26'th Feb 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics
10:21am, Thursday, 26'th Feb 2026
Evaluate the expected performance of Xeris Biopharma (XERS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
07:30am, Tuesday, 17'th Feb 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
08:52am, Tuesday, 03'rd Feb 2026
Recorlev drives robust top-line expansion, while Gvoke and Keveyis provide stable revenue streams in niche, high-need markets, supporting operational leverage. XP-8121, a once-weekly injectable levoth
Analyzing Soleno Therapeutics (NASDAQ:SLNO) & Xeris Biopharma (NASDAQ:XERS)
01:28am, Thursday, 29'th Jan 2026
Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Soleno Therapeutics (NASDAQ: SLNO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
07:00am, Thursday, 08'th Jan 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights. "Our
Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 Shares of Stock
05:25am, Tuesday, 06'th Jan 2026
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The stock was sold
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:15pm, Friday, 02'nd Jan 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma (NASDAQ:XERS) Shares Gap Up – What’s Next?
02:14am, Friday, 02'nd Jan 2026
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $7.31, but opened at $7.89. Xeris Biopharma shares l
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday
06:49pm, Wednesday, 31'st Dec 2025
It wasn't because of any news coming from the biotech. Rather, a rival's setback brought the bulls into its stock.
Squarepoint Ops LLC Purchases 268,572 Shares of Xeris Biopharma Holdings, Inc. $XERS
05:04am, Sunday, 21'st Dec 2025
Squarepoint Ops LLC boosted its position in Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) by 1,679.1% in the undefined quarter, according to the company in its most recent Form 13F filing with the Sec
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Xeris Biopharma (NASDAQ:XERS)
03:30am, Monday, 08'th Dec 2025
Xeris Biopharma (NASDAQ: XERS - Get Free Report) and ARS Pharmaceuticals (NASDAQ: SPRY - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
07:00am, Monday, 01'st Dec 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Moderate Buy” from Analysts
01:21am, Tuesday, 25'th Nov 2025
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat Ratings reports. One r
Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript
11:16am, Thursday, 06'th Nov 2025
Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications Joh
